The purpose of this legislation is to enhance transparency and reporting related to over-the-counter (OTC) drug monograph activities. It aims to improve the oversight of OTC drugs, ensuring that the Food and Drug Administration (FDA) can effectively manage and monitor these products for safety and efficacy. Key provisions of the legislation include requirements for the FDA to produce annual performance reports starting in fiscal year 2026.